Treatment of Acne Scars With Hyaluronic Acid: An Improved Approach

July 2013 | Volume 12 | Issue 7 | Original Article | e121 | Copyright © 2013

Shlomit Halachmi, MD PhD,a Dan Ben Amitai MD,b,d and Moshe Lapidoth MD MPHc,d

aHerzelia Skin and Laser Center, Herzelia Pituach, Israel bPediatric Dermatology Unit, Schneider Children's Medical Center of Israel, Israel cLaser Unit, Department of Dermatology, Rabin Medical Center, Petach Tikva, Israel dSackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Abstract

BACKGROUND: Acne scarring is a prevalent and challenging cosmetic issue, which is often addressed by multiple modalities. A low-viscosity non-animal stabilized hyaluronic acid (NASHA) dermal filler, injected in microdoses into the mid-to-superficial dermis, may provide a useful new approach to improving the appearance of depressed acne scars.
MATERIALS and METHODS: Twelve consecutive patients with moderate to severe acne scarring, who had completed a series of fractional laser resurfacing, underwent microinjections of 20 mg/mL hyaluronic acid (HA) gel into discrete depressed acne scars on the face.
RESULTS: Immediate visual improvement was observed in all lesions. The procedure was well tolerated. Adverse events were limited to transient pinpoint bleeding at the injection site.
CONCLUSION: Microinjection of low viscosity HA offers a valuable technique for the treatment of discrete depressed acne scars.

J Drugs Dermatol. 2013;12(7):e121-e123.

Purchase Original Article

Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.

Download the original manuscript as it was published in the JDD.

Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.

To get access to JDD's full-text articles and archives, upgrade here.

Save an unformatted copy of this article for on-screen viewing.

Print the full-text of article as it appears on the JDD site.

→ proceed | ↑ close
table 1

INTRODUCTION

Hyaluronic acid (HA) is a glycosaminoglycan composed of alternating D-glucuronic acid and N-acetyl- D-glucosamine monosaccharide residue. These are cross-linked to form long unbranched chains, which form an anionic biopolymer. The 3-dimensional structure forms a space-occupying molecule, and the chemical makeup draws a large volume of water to the compound. Due to its combination of properties, endogenous HA contributes turgor and elasticity to the dermis.

Hyaluronic acid has become the leading dermal filler due its combination of low allergenicity, high biocompatibility as demonstrated in ocular and intra-articular uses, and longevity. It is suitable for injection into facial skin, where, in addition to providing immediate and short-term augmentation, it appears to induce longer-term effects by stimulating collagenesis by native fibroblasts.1,2 Improvements in its in vivo longevity by cross-linking have further boosted its popularity. To maximize its utility and range of applications, HA has been prepared in a variety of forms, which vary in viscosity and formulation. Hyaluronic acid's viscoelastic properties are a function of the length of the molecular chains of the polymer, cross-linking, concentration, and particle size.3 Medium viscosity HA is best for moderate lines and wrinkles, such as glabellar lines and nasolabial folds. It is injected into the mid-to-deep dermis. Finer HA formulations are available for correction of fine facial lines, such as perioral and periorbital rhytids, and are injected in the superficial dermis. Specialized formulations are designed to be injected into the lip, while others indicated for restoring volume lost due to natural aging or HIV-related lipoatrophy are injected into the subcutaneous or supraosteal regions.

Restylane® Vital is a low-viscosity HA gel, available in 12 mg/mL or 20 mg/mL. It is injected with a metered dose injector that deposits 10 μL per injection site (Figure 1).

Given the properties, superficial injection, and microdosing delivery technique, Restylane Vital is an excellent candidate product for the treatment of ice pick acne scars. Twelve patients, whose moderate to severe ice pick acne scars had responded well overall to fractional laser resurfacing but who exhibited residual deep focal ice pick scars, were treated with Restylane Vital. The improvement was immediate, as expected, and the treatment was well tolerated by all patients. Restylane Vital therefore appears to offer an improved treatment modality for the treatment of acne scarring.

MATERIALS AND METHODS

Twelve patients (7 men and 5 women) aged 19 to 54 years were treated. All had completed 2 to 5 (mean 3.2) treatments with fractional laser resurfacing for depressed facial acne scars using either erbium (Pixel 2940nm Er:YAG Module; Alma Lasers™ Ltd, Israel) or CO2 (UltraPulse® Fractional CO2; Lumenis® Ltd, Israel). They exhibited good overall improvement, with no adverse events, but retained scattered deep ice pick scars. At 1 to 2 months after the final laser treatment, they were

↑ back to top


Related Articles